Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting ...

A technological revolution is helping Scripps Research scientists see the molecules that undermine human health, from ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

AbbVie’s Humira (adalimumab) maintained exclusivity for two decades despite the main patent expiring in 2016. AbbVie secured ...

(Spencer Platt | Getty Images) President Trump signed an executive action Tuesday ... like blockbuster rheumatoid arthritis ...

Rova-T was supposed to be the cancer drug that would bolster AbbVie’s revenues as revenues from the $20bn a year Humira (adalimumab ... perhaps with the usual pictures of shrinking tumours ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

The prescribed dosage for Humira (adalimumab) may vary depending on a person’s individual treatment plan. Other factors, including specific diagnosis, body weight, and medical history ...

It is the ninth Humira biosimilar approved by the FDA and the fourth to receive interchangeability status. The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the ...

AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...